Saturday, January 5, 2008

Assignments Go Online

I am publishing some of my MBA assignments from Nottingham Business School of Nottingham Trent University. All MBA works include official assessment made by module tutor on its last page. Some minor changes (like in formating) may differ the web versions from works submitted to NTU office but the content is identical.




There is an interesting point in the finance assignment that prognosis on selected biotech stocks returns put down there turned into reality as measured in 11 months (3rd January 2008) after the analyses. It is understood that the prognosis is linked to huge potential profits as described bellow. As major biotechnology companies were analyzed following fundamental conclusions on their investment prospects are present in the work dated February 15th 2007:
Genzyme
This stock (Genzyme) can be good portfolio investment for those who are willing to accept risk associated with biotechnology stocks.
Genentech
Investors should be rather careful about too high (P/E) ratio of Genentech. For company which now has highest capitalization in biotech sector it is not sustainable to hold unrealistically high P/Es over long time period. The company produced superb returns from 2003 to 2005 but failed to substantially rise profit. In this case high P/E may signal that shares are “overvalued”.
Gilead Sciences
... as company prospects are still good it may be worth higher share price.

The table bellow show the stock prices from 15th February 2007 until recent - 3rd January 2008 and confirm correctness of the assessment.
There are not any further (not accomplished) prognosis in the work. However, as I assume to publish more on subject of equity markets in this blog do not forget to check it in future or bookmark the page if interested in other valuable hints.

In addition I also publish my diploma thesis from Pharmaceutical Faculty dealing with genotyping in Alzheimer disease.


In any handling with these works my copyrights shall be fully recognized.

No comments: